Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AM1476 Phase I SAD/MAD Study in Healthy Subjects
NCT04691115Phase 1Completed
- Sponsor
- AnaMar
- Start
- Dec 2020
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AM1476 in systemic sclerosis (SSc) (14 arms), sponsored by AnaMar. Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events at 7 weeks. Started Dec 2020; status: completed.
02
Drugs
AM1476
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT04691115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04691115.